London – Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at four years for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localised treatment. These results from HIMALAYA will be presented today at the 2023 European Society for …
Ottawa – In Canada and around the world, there is increasing interest in the potential therapeutic uses of psychedelics to treat substance use and mental health challenges. However, more research evidence is needed to better understand if psychedelic-assisted psychotherapy is a safe and effective treatment option for people experiencing mental illness and addictions. Carolyn Bennett, Minister of Mental Health and …
Accelerator and nuclear reactors, in partnership with First Nations and biomanufacturing, to receive up to $35 million to support the development, production, advancement and distribution of medical isotopes used in fight against cancer and in diagnostic imaging Tiverton – The Government of Canada continues to deliver on its promise to rebuild and strengthen the biomanufacturing and life sciences sector across …
Ottawa – The latest edition of the Patented Medicine Prices Review Board (PMPRB) Meds Pipeline Monitor reports that oncology continued to dominate the therapeutic mix of the drug pipeline in 2022, with cancer treatments representing nearly one third (30%) of medicines in all phases of clinical trials. Treatments for infectious diseases held the second largest share of the pipeline, at 15%, due …
Activities supported through this investment reflect priority areas identified in the Framework for Diabetes in Canada Toronto – Diabetes is one of the most common chronic diseases, affecting approximately 3.6 million Canadians, with more than 200,000 new cases diagnosed every year. Diabetes has significant impacts on the lives of the people that it directly affects, as well as their families …
London – Everyone wishes to lose weight but medication for weight loss is less and people need to get involved in strenuous exercise regimens and extreme diets to shed extra kilos. Now the results of two clinical trials, presented during American Diabetes Association Scientific Sessions, show pharmaceutical industry has come far in developing a pill-based weight loss medication. Popular medications, …
London – Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement inhibitor approved for the treatment of gMG in China. The approval by the National Medical Products Administration (NMPA) in China was based on comprehensive results from the Phase III …
Improving health outcomes for people at risk of substance-related harms and overdose in the region of Ottawa Ottawa – Every day, families and communities across the country lose loved ones to overdoses from the increasingly toxic drug supply. Collectively, through harm reduction services, treatment, as well as prevention efforts alongside all levels of government, the Government of Canada is working to …
KIRKLAND – Pfizer Canada ULC announces the launch of its Healthcare Hub, an initiative with Canadian tech and innovation startups to scale up health solutions, with the goal of enhancing outcomes and the patient experience in important areas of need in Canadian healthcare. Innovations will be brought to life through a partnership between Pfizer Canada and Canadian technology supercharger Communitech. …
Texas – A research group at Baylor College of Medicine in Houston, Texas, did a study on oral administration of a commercially available probiotic bacterial strain and found it improved dry eye disease in an animal model. The findings was presented at ASM Microbe 2023, the annual meeting of the American Society for Microbiology. According to Medical Xpress, 1 in …
